FDA is withdrawing this collection. The next actions will be (1) a non-substantive change request to merge this collection into 0919-0001, and (2) a discontinuation for this control number.
Inventory as of this Action
Requested
Previously Approved
01/31/2015
36 Months From Approved
03/06/2015
72
0
72
3,672
0
3,672
243,648
0
243,648
Under these requirements, applicants must submit data on all bioequivalence (BE) studies, including studies that do not meet passing bioequivalence criteria, which are performed on a drug product formulation submitted for approval under an Abbreviated New Drug Application (ANDA), or in an amendment to an ANDA that contains BE studies. Applicants must submit information from all BE studies, both passing and nonpassing, conducted by the applicant on the same drug product formulation as that submitted for approval under an ANDA, amendment, or supplement.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.